The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•11 March 2026•

1 min read

BioNTech Shifts to Oncology Amid Leadership Transition and Stock Volatility

Key Facts

1BioNTech plans to have 15 ongoing Phase 3 oncology trials by the end of 2026.

2Morgan Stanley set a price target of $128 for BioNTech, suggesting a potential 52.58% upside.

BioNTech SE is strategically pivoting its focus toward oncology and next-generation mRNA technology as it transitions from its COVID-19 vaccine success. The company aims to have 15 ongoing Phase 3 clinical trials in the oncology sector by the end of 2026. Despite a projected net loss of €1.14 billion for 2025, BioNTech maintains a robust financial position with €17.2 billion in cash reserves. Morgan Stanley has set a bullish price target of $128 for the stock, implying a potential upside of over 52%. However, the departure of co-founders Ugur Sahin and Özlem Türeci to launch a new venture has triggered a 21% decline in share price. This leadership transition creates a period of uncertainty even as the firm pursues long-term growth in cancer treatment.